{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:36Z","timestamp":1792177716820,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40265-024-02091-8","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T11:09:18Z","timestamp":1726052958000},"page":"1337-1346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-2096","authenticated-orcid":false,"given":"Panagiotis I.","family":"Georgianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Vaios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Liakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"2091_CR1","unstructured":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709\u201333."},{"key":"2091_CR2","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2215\/CJN.10271110","volume":"6","author":"YT Debella","year":"2011","unstructured":"Debella YT, Giduma HD, Light RP, Agarwal R. Chronic kidney disease as a coronary disease equivalent\u2014a comparison with diabetes over a decade. Clin J Am Soc Nephrol. 2011;6:1385\u201392.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2091_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.kint.2017.01.030","volume":"92","author":"CP Wen","year":"2017","unstructured":"Wen CP, Chang CH, Tsai MK, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92:388\u201396.","journal-title":"Kidney Int"},{"key":"2091_CR4","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","volume":"26","author":"S Thompson","year":"2015","unstructured":"Thompson S, James M, Wiebe N, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26:2504\u201311.","journal-title":"J Am Soc Nephrol"},{"key":"2091_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeew D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"2091_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"2091_CR7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102:974\u201389.","journal-title":"Kidney Int"},{"key":"2091_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105:684\u2013701.","journal-title":"Kidney Int"},{"key":"2091_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30\u201348.","journal-title":"Ann Intern Med"},{"key":"2091_CR10","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892\u2013903.","journal-title":"N Engl J Med"},{"key":"2091_CR11","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of Aliskiren for Type 2 diabetes. N Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"2091_CR12","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","volume":"25","author":"AK Ahmed","year":"2010","unstructured":"Ahmed AK, Kamath NS, El KM, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010;25:3977\u201382.","journal-title":"Nephrol Dial Transplant"},{"key":"2091_CR13","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387:2021\u201332.","journal-title":"N Engl J Med"},{"key":"2091_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","volume":"102","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Agarwal R, Alpers CE, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102:248\u201360.","journal-title":"Kidney Int"},{"key":"2091_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2091_CR16","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2091_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2174\/1381612827666210119102409","volume":"27","author":"PI Georgianos","year":"2021","unstructured":"Georgianos PI, Vaios V, Dounousi E, et al. Mechanisms for cardiorenal protection of SGLT-2 inhibitors. Curr Pharm Des. 2021;27:1043\u201350.","journal-title":"Curr Pharm Des"},{"key":"2091_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"2091_CR19","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","volume":"34","author":"RA Fletcher","year":"2023","unstructured":"Fletcher RA, Jongs N, Chertow GM, et al. Effect of SGLT2 inhibitors on discontinuation of renin-angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials. J Am Soc Nephrol. 2023;34:1965\u201375.","journal-title":"J Am Soc Nephrol"},{"key":"2091_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2924","author":"JE Blau","year":"2017","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017. https:\/\/doi.org\/10.1002\/dmrr.2924.","journal-title":"Diabetes Metab Res Rev"},{"key":"2091_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348\u201355.","journal-title":"Diabetes Obes Metab"},{"key":"2091_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2174\/1574886314666190206164647","volume":"14","author":"M Singh","year":"2019","unstructured":"Singh M, Sharma R, Kumar A. Safety of SGLT2 inhibitors in patients with diabetes Mellitus. Curr Drug Saf. 2019;14:87\u201393.","journal-title":"Curr Drug Saf"},{"key":"2091_CR23","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","volume":"170","author":"SJ Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170:764\u20139.","journal-title":"Ann Intern Med"},{"key":"2091_CR24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","volume":"62","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Li Q, Perkovic V, et al. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia. 2019;62:926\u201338.","journal-title":"Diabetologia"},{"key":"2091_CR25","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group. SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801.","journal-title":"Lancet"},{"key":"2091_CR26","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","volume":"43","author":"A Verma","year":"2022","unstructured":"Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022;43:3781\u201391.","journal-title":"Eur Heart J"},{"key":"2091_CR27","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","volume":"6","author":"PI Georgianos","year":"2021","unstructured":"Georgianos PI, Agarwal R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int Rep. 2021;6:2281\u201391.","journal-title":"Kidney Int Rep."},{"key":"2091_CR28","volume":"10","author":"EY Chung","year":"2020","unstructured":"Chung EY, Ruospo M, Natale P, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020;10: CD007004.","journal-title":"Cochrane Database Syst Rev"},{"key":"2091_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C, et al. Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study. Am J Kidney Dis. 2022;80:164\u201373.","journal-title":"Am J Kidney Dis"},{"key":"2091_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/ndt\/gfz263","volume":"36","author":"JB Wetmore","year":"2021","unstructured":"Wetmore JB, Yan H, Horne L, Peng Y, Gilbertson DT. Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrol Dial Transplant. 2021;36:826\u201339.","journal-title":"Nephrol Dial Transplant"},{"key":"2091_CR31","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2091_CR32","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2091_CR33","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"2091_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021;17:227\u201344.","journal-title":"Nat Rev Nephrol"},{"key":"2091_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","volume":"145","author":"AM Shaman","year":"2022","unstructured":"Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: a pooled analysis of SUSTAIN 6 and LEADER trials. Circulation. 2022;145:575\u201385.","journal-title":"Circulation"},{"key":"2091_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2091_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2091_CR38","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","volume":"38","author":"P Rossing","year":"2023","unstructured":"Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38:2041\u201351.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2091_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"key":"2091_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am J Prev Cardiol. 2023;14: 100502.","journal-title":"Am J Prev Cardiol."},{"key":"2091_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-024-00629-x","author":"M Tobaiqy","year":"2024","unstructured":"Tobaiqy M. A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment. Pharmacol Rep. 2024. https:\/\/doi.org\/10.1007\/s43440-024-00629-x.","journal-title":"Pharmacol Rep"},{"key":"2091_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13864","volume":"53","author":"PI Georgianos","year":"2022","unstructured":"Georgianos PI, Eleftheriadis T, Liakopoulos V. Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet? Eur J Clin Invest. 2022;53: e13864.","journal-title":"Eur J Clin Invest"},{"key":"2091_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A, et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol. 2021;52:642\u201352.","journal-title":"Am J Nephrol"},{"key":"2091_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03133-0","author":"JFE Mann","year":"2024","unstructured":"Mann JFE, Rossing P, Bakris G, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03133-0.","journal-title":"Nat Med"},{"key":"2091_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","volume":"7","author":"M Provenzano","year":"2022","unstructured":"Provenzano M, Jongs N, Vart P, et al. The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney Int Rep. 2022;7:436\u201343.","journal-title":"Kidney Int Rep."},{"key":"2091_CR46","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P, Anker SD, Filippatos G, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care. 2022;45:2991\u20138.","journal-title":"Diabetes Care"},{"key":"2091_CR47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/dom.14883","volume":"25","author":"P Rossing","year":"2023","unstructured":"Rossing P, Agarwal R, Anker SD, et al. Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab. 2023;25:407\u201316.","journal-title":"Diabetes Obes Metab"},{"key":"2091_CR48","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460\u201370.","journal-title":"Circulation"},{"key":"2091_CR49","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","volume":"38","author":"JB Green","year":"2023","unstructured":"Green JB, Mottl AK, Bakris G, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023;38:894\u2013903.","journal-title":"Nephrol Dial Transplant"},{"key":"2091_CR50","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"2091_CR51","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543\u201351.","journal-title":"N Engl J Med"},{"key":"2091_CR52","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1056\/NEJMp048144","volume":"351","author":"JJ McMurray","year":"2004","unstructured":"McMurray JJ, O\u2019Meara E. Treatment of heart failure with spironolactone\u2013trial and tribulations. N Engl J Med. 2004;351:526\u20138.","journal-title":"N Engl J Med"},{"key":"2091_CR53","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2215\/CJN.02980322","volume":"17","author":"KR Tuttle","year":"2022","unstructured":"Tuttle KR, Wong L, Wendy P, et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol. 2022;17:1092\u2013103.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02091-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T08:18:40Z","timestamp":1732781920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02091-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02091-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"26 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors (P.I.G., V.V., T.K., V.L.) report no conflicts of interest relevant to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"No external funds were used in the preparation of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P.I.G. reviewed the literature and drafted the initial version of the manuscript. V.V., T.K., and V.L. reviewed the literature and edited the manuscript. All authors read and approved the final version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable because this is a review article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}